IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION May 2026 Update Filed in 2016 and centralized in the Eastern District of Pennsylvania, the Generic Pharmaceuticals Pricing Antitrust Litigation (MDL No. 2724) remains one of the largest and most complex antitrust cases in the U.S. The litigation alleges that multiple generic drug manufacturers conspired to fix prices, allocate markets, and limit competition across hundreds of generic drugs. Current Status (2026) This

Over $115.2 Million via Pharmaceutical Benefit Plan Settlements, separate from the Generic Pharmaceuticals Pricing Antitrust Litigation. Overview There are typically several active lawsuits and/or class action settlements that fall into the category of “pharmaceutical benefit plan settlements.” Under these cases, it is generally alleged that businesses with self-insured health plans overpaid for drugs purchased on behalf of their employees due to artificially inflated and/or

Update: Preliminary approval has been granted (March 20, 2026) for a new Acute Care Hospital Opioids Settlement in San Miguel Hospital Corp., et al. v. Richard Sackler, et al. (D.N.M.), establishing a settlement fund of approximately $174.2 million . This settlement represents an additional recovery opportunity specifically for Acute Care Hospitals, stemming from allegations that members of the Sackler family and related entities contributed to the opioid epidemic and the

For most merchants, payment processing is just part of doing business—until the costs start adding up. What many don’t realize is that they may be entitled to recover a portion of the fees they’ve already paid. Every transaction carries layers of expense—interchange fees, network fees, processor markups, and compliance costs—that quietly erode margins over time. These costs are often accepted as fixed. They’re not. Many of these practices have been challenged in court, creati

The $2.67 billion Blue Cross Blue Shield Provider Settlement addressed market power. The $575 million Sutter Health Settlement challenged restrictive contracting practices. The ongoing Acute Care Hospital Opioid Settlements focused on accountability and cost recovery. Each of those cases examined large-scale structural conduct in healthcare. The next wave of healthcare litigation is shifting direction. It is less about traditional market share disputes and more about syste

In our previous blog, we outlined the core categories of class actions where MCAG focuses its filing and recovery efforts. As we head into 2026, this follow-up highlights the specific cases within those categories that continue to warrant close attention. Our Research team reviews daily federal docket activity and tracks cases throughout their lifecycle. We focus on matters that show real momentum, affect broad segments of industry, and have practical relevance for our clien

As we close out the year, it’s a good moment to step back and take stock of the class action landscape—and, just as importantly, to reaffirm where MCAG focuses its efforts on behalf of our clients. Each year brings a steady stream of new settlements, court rulings, and headline-grabbing cases. But not every class action represents a meaningful or appropriate recovery opportunity for organizations. At MCAG, our role is not to chase volume—it is to apply experience, judgment, a

Merchants may be eligible for additional recoveries beyond the Visa Mastercard and Discover Merchant Settlements. As the payments industry evolves, more class-action settlements are emerging for merchants, including those who absorbed fraud losses due to EMV liability shifting. When EMV chip cards rolled out in 2015, liability for fraudulent transactions shifted to merchants that didn’t use EVM-compliant terminals. Studies show fraud loss rates for non-EMV transactions rose f

Why It Matters For years, the skyrocketing price of insulin has been at the forefront of America’s healthcare debate, and now it’s at the center of one of the most significant pharmaceutical pricing cases in history. The ongoing Insulin Pricing Multidistrict Litigation (MDL No. 3080) consolidates lawsuits against the nation’s three largest insulin manufacturers and three major pharmacy benefit managers (PBMs), who together control roughly 80% of the U.S. prescription drug ma

Artificial Intelligence (AI) is no longer just a buzzword—it’s reshaping nearly every industry. From healthcare to financial services, AI...

Pharmacies that paid for e-prescriptions routed through the Surescripts network may now have the opportunity to recover a portion of...

Class actions are often misunderstood. Many businesses assume they aren’t eligible, that recoveries are too small, or that the process is...

A complicated settlement, made simple. The Discover Settlement is here—and it’s unlike anything we’ve seen before. It’s highly technical, involves multiple claimant types, and is filled with terms and rules that can be confusing even for industry insiders. That’s where MCAG comes in. As the nation’s leading experts in complex settlements, we’ve been tracking the details from day one. We’ve read the fine print, decoded the jargon, and mapped out exactly what this settlement me

This July, MCAG proudly marked its third year volunteering at the Greater Toledo Classic Golf Tournament in support of the Ronald...

The past six months have marked a major period for antitrust class action settlements, with two historic deadlines: the Payment Card...

Every year, billions of dollars from class action and commercial settlements go unclaimed. That’s right — billions. And if your business...

After more than a decade of litigation, Sutter Health has agreed to pay $228.5 million to settle claims that it abused its market...

The process of filing pharmaceutical class action claims can be a daunting task for healthcare providers, pharmacy benefit managers...

In recent years, technology has dramatically reshaped the way class action settlements are managed, and the changes are only...

Over the past decade, women have made significant strides in the legal profession, and their presence in law continues to grow. According...